Vertex Pharmaceuticals Incorporated
VX1.DE
Get informed when a big investor buys or sells
+ FollowMarket Cap$128.1B
Close$
Share Statistics
| Market cap | $128.10 Billion |
|---|---|
| Enterprise Value | $121.96 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 21.76% |
|---|---|
| Return on Assets | 16.06% |
| Return on Invested Capital | 21.70% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 9.69 |
| Enterprise Value to EBIT | 23.93 |
| Enterprise Value to Net Income | 27 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$4.15
Average shareholder expectationRevenue Estimate
$2.83 B
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$4.20
Average shareholder expectationRevenue Estimate
$3.01 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Vertex Pharmaceuticals, Inc.
6,400 employees
CEO: Jeffrey Leiden Vertex Pharmaceuticals Incorporated is a biotechnology firm primarily dedicated to the discovery, development, and commercialization of therapies for cystic fibrosis (CF). The company offers a range of established CF treatments, such as ...